Catalyst Dossier · compiled by CeliA 🧫

Cosmo Pharmaceuticals N.V. (COPN.SW)

Pharmaceutical Preparations · market cap $1.2B · as of 2026-07-03

Research and calibrated estimates, not financial advice — verify before acting.

Next catalyst

None scheduled

Pipeline

programs

Upcoming events

next 90d+

Dossier

Ready

cached

Non-US-listed company. Financial statements and forensic scores here come from US SEC filings (10-K/10-Q), which foreign issuers don’t file — those sections may be blank. The catalyst calendar, pipeline, approval odds, price context and (where covered) analyst targets still apply.

Cosmo Pharmaceuticals N.V. (COPN.SW) is a Swiss-listed specialty pharma company with 324 employees and a market cap of approximately $1.24B. Its pipeline is anchored by Rifamycin SV MMX in Phase 3 for Traveler's Diarrhea, with additional assets in infectious diarrhea, IBS-D, and colorectal cancer detection/prevention at Phase 2. No near-term catalysts are publicly flagged in the provided data.

The catalyst path

No upcoming catalysts in our calendar.

Pipeline

Asset	Phase	Indication
Rifamycin SV MMX	Phase 3	Traveler's Diarrhea
400 mg Rifamycin SV dosage	Phase 2	Infectious Diarrhoea
Rifamycin SV 600mg t.i.d.	Phase 2	Diarrhea-predominant Irritable Bowel Syndrome
Methylene Blue MMX tablets	Phase 2	Colorectal Cancer
Methylene Blue MMX®	Phase 3	Colorectal Cancer
Methylene Blue MMX 25 mg modified release tablets	Phase 2	Colon Staining in Preparation for Colonoscopy

The full dossier is a Pro feature

Thesis, bull & bear, the if-approved scenario, financials, smart-money signals and risks — compiled by CeliA. The catalyst path & pipeline above are free.

See Pro

Sources & data

SEC filings — EDGAR filings for COPN.SW (10-K, 10-Q, S-3, 13D/G, Form 4)
Clinical trials — 6 registered trials on ClinicalTrials.gov (per-trial NCT links in the pipeline)
Market & financial data — Financial Modeling Prep / financialdata.net — prices, statements, key metrics, insider & institutional filings.
Regulatory — openFDA, FDA advisory & PDUFA calendars.

Approval odds use historical phase base rates; the if-approved scenario is illustrative (see its note). Figures trace to the sources above — verify before acting.

Data from CatalystAlert (ClinicalTrials.gov, SEC EDGAR, openFDA, Financial Modeling Prep). Compiled by CeliA. Not financial advice.